Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03982030
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:11.528159+00:00
Published At
2023-05-03T00:00:00+00:00
Record Updated At
2023-05-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Gram-Positive Bacterial Infections", "Soft Tissue Infections"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-05-03"
protocolSection.identificationModule.nctId
"NCT03982030"
protocolSection.identificationModule.officialTitle
"An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Gram-Positive Bacterial Infections (protocolSection.conditionsModule.conditions)
  • Soft Tissue Infections (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.